Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Béraud T, Gómez F
Cancer. 1986 Mar 15;57(6):1171-80. doi: 10.1002/1097-0142(19860315)57:6<1171::aid-cncr2820570618>3.0.co;2-x.
The aims of this study were as follows: to confirm that the presence of estrogen (ER) and progesterone (PgR) receptors is an indicator of clinical behavior of human breast cancer independent of other known prognostic factors; to seek clinical correlates of those receptor values that best predict the overall disease evolution; and to determine the relative prognostic importance of PgR versus ER. The clinical records of 547 patients, the follow-up of some extending to 6 years, were analyzed in retrospect. Patients were placed into one of four disease stages and also in three groups according to the degree of axillary node involvement. In each group the prognostic value of receptors for patient survival, disease-free interval and, in case of metastasis or local recurrence, the response to endocrine treatment or chemotherapy were studied. The break point in the spectrum of receptor concentrations with regard to survival, disease-free interval, and response to treatment was greater than or equal to 20 for ER+, greater than or equal to 15 for PgR+, and less than 5 for both ER- and PgR- reported in fmol/mg protein. Survival and disease-free interval showed positive correlations with ER and PgR (P less than 0.001-less than 0.0003). When disease stage or node involvement were considered, these correlations were found essentially in Stage II and node involvement in more than three nodes, where patients had longer survival and disease-free interval if ER and PgR were positive (P less than 0.05-less than 0.0003). Estrogen receptor was a more sensitive prognostic indicator than PgR, and the combination ER+/PgR+ showed a correlation equivalent to ER+/PgR-. The correct prediction percentages of the response of patients to endocrine treatment were 77% if ER+, 69% if PgR+, and 79% if both ER+ and PgR+. However, the correct prediction percentage of the response to chemotherapy was of 50%. These results show that ER and PgR are prognostic factors for survival and disease-free interval mainly on patients at Stage II and node involvement of greater than three, with ER demonstrating a better predictive value than PgR. The measurement of these receptors provides a prognostic index for response to endocrine therapy but is without value in predicting the response to chemotherapy.
证实雌激素（ER）和孕激素（PgR）受体的存在是人类乳腺癌临床行为的一个指标，独立于其他已知的预后因素；寻找那些能最佳预测整体疾病进展的受体值的临床相关因素；并确定PgR与ER相对的预后重要性。对547例患者的临床记录进行了回顾性分析，部分患者的随访时间长达6年。患者被分为四个疾病阶段之一，还根据腋窝淋巴结受累程度分为三组。在每组中，研究了受体对患者生存、无病间期的预后价值，以及在发生转移或局部复发时，对内分泌治疗或化疗的反应。就生存、无病间期和治疗反应而言，受体浓度谱中的断点为：ER+时大于或等于20，PgR+时大于或等于15，ER-和PgR-时均小于5（以fmol/mg蛋白计）。生存和无病间期与ER和PgR呈正相关（P小于0.001 - 小于0.0003）。当考虑疾病阶段或淋巴结受累情况时，这些相关性主要见于II期以及淋巴结受累超过三个的情况，在此情况下，如果ER和PgR呈阳性，患者的生存和无病间期更长（P小于0.05 - 小于0.0003）。雌激素受体是比PgR更敏感的预后指标，ER+/PgR+组合显示出与ER+/PgR-相当的相关性。患者对内分泌治疗反应的正确预测百分比为：ER+时为77%，PgR+时为69%，ER+和PgR+时为79%。然而，对化疗反应的正确预测百分比为50%。这些结果表明，ER和PgR是II期且淋巴结受累大于三个的患者生存和无病间期的预后因素，其中ER的预测价值优于PgR。这些受体的检测为内分泌治疗反应提供了一个预后指标，但对预测化疗反应没有价值。
